2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid (N[3-(4,4-diphenylpiperidin-1-yl)propyl]amide methyl ester)

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid (N[3-(4,4-diphenylpiperidin-1-yl)propyl]amide methyl ester)
• 英文别名: (+)-SNAP 5089；(-)-SNAP 5089；SNAP 5089；SNAP5089；2,6-Dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid N-[3-(4,4-diphenylpiperidine-1-yl)propyl]amide methyl ester；3-Pyridinecarboxylic acid, 5-[[[3-(4,4-diphenyl-1-piperidinyl)propyl]amino]carbonyl]-1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-, methyl ester；methyl 5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
• 化学式: C₃₆H₄₀N₄O₅
• 分子量: 608.737
• InChiKey: FIIXCJGBCCCOQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid (N[3-(4,4-diphenylpiperidin-1-yl)propyl]amide methyl ester) 、 盐酸 、 乙醚 、 乙酸乙酯 以 乙醇 为溶剂， 以gave 91 mg of yellow crystalline solid的产率得到2,6-Dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid N-[3-(4,4-diphenylpiperidin-1-yl)-propyl]amide methyl ester hydrochloride hydrate
  参考文献：
  名称：

  .alpha..sub.1C specific compounds to treat benign prostatic hyperplasia

  摘要：

  本发明提供了一种治疗受试者良性前列腺增生的方法，包括向受试者施用治疗有效量的α1C拮抗剂，该拮抗剂（a）与人类α1C肾上腺素能受体结合的亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的亲和力高100倍以上；（b）与人类α2肾上腺素能受体结合的亲和力比其与该α1C肾上腺素能受体结合的亲和力低100倍以上。本发明还提供了一种抑制前列腺组织收缩的方法，包括将前列腺组织与有效的抑制收缩量的α1C拮抗剂接触，该拮抗剂（a）与人类α1C肾上腺素能受体结合的亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的亲和力高100倍以上；（b）与人类α2肾上腺素能受体结合的亲和力比其与该α1C肾上腺素能受体结合的亲和力低100倍以上。

  公开号：

  US05990128A1
• 作为产物：
  描述：

  acetoacetic acid N-[3-(4,4-diphenylpiperidin-1-yl)propyl]amide 、 β-氨基巴豆酸甲酯 、 对硝基苯甲醛 在 氩 、 二氯甲烷 、 水 、 magnesium sulfate 、 SiO2 、 乙酸乙酯 、 甲醇乙酸乙酯 作用下， 以 异丙醇 为溶剂， 反应 60.0h， 以to give 147.8 mg (25%) of yellow solid的产率得到2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid (N[3-(4,4-diphenylpiperidin-1-yl)propyl]amide methyl ester)
  参考文献：
  名称：

  Compositions comprising alpha-1C specific compounds

  摘要：

  一种治疗良性前列腺增生的方法，包括向患者施用一种与人类α1C肾上腺素能受体结合的化合物，其结合亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素能受体的结合亲和力比其与该α1C肾上腺素能受体结合的亲和力低十倍以上。提供了符合这些标准的化合物。

  公开号：

  US20030022900A1

文献信息

• Use of .alpha..sub.1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05403847A1

  公开（公告）日：1995-04-04

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生症的方法，包括向受试者施用一种治疗有效量的化合物，该化合物与人类α1C肾上腺素能受体结合的结合亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的结合亲和力高出十倍以上，并且与人类α2肾上腺素能受体的结合亲和力比其与此类α1C肾上腺素能受体结合的结合亲和力低出十倍以上。提供了符合这些标准的化合物。
• USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA
  申请人：——

  公开号：US20020032219A1

  公开（公告）日：2002-03-14

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; 1A adrenergic receptor, a human &agr; 1B adrenergic receptor, and a human histamine H 1 receptor, and, binds to a human &agr; 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; 1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生症的方法，包括向患者施用一种治疗有效量的化合物，该化合物与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与α1C肾上腺素受体结合的亲和力低十倍以上。提供符合这些标准的化合物。
• Compositions comprising alpha-1C specific compounds
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030022900A1

  公开（公告）日：2003-01-30

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; 1A adrenergic receptor, a human &agr; 1B adrenergic receptor, and a human histamine H 1 receptor, and, binds to a human &agr; 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; 1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者施用一种与人类α1C肾上腺素能受体结合的化合物，其结合亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素能受体的结合亲和力比其与该α1C肾上腺素能受体结合的亲和力低十倍以上。提供了符合这些标准的化合物。
• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  本发明涉及具有以下结构的新型芳香胺化合物：##STR1## 其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1-C.sub.6烷基，C.sub.1-C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1-C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1-C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1-C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1-C.sub.6直链或支链烷基或苯基，C.sub.1-C.sub.6直链或支链烷氧基或OH。此外，本发明还包括使用这些化合物治疗良性前列腺增生、降低眼压和抑制胆固醇合成。
• Use of .alpha.-1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05578611A1

  公开（公告）日：1996-11-26

  The subject invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, a human histamine H.sub.1 receptor and .alpha..sub.2 adrenergic receptor. The subject invention also provides a method of inhibiting contraction of prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of such compound.

  该发明涉及一种治疗良性前列腺增生的方法，包括向受体内投与一种结合人类α1C肾上腺素受体的化合物，该化合物的结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体、人类组胺H1受体和α2肾上腺素受体结合的结合亲和力高出十倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，包括使用该化合物的有效抑制收缩量与前列腺组织接触。